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Abstract
Anti HCV vaccine is not currently available and the present antiviral therapies fail to cure approximately half of the
treated HCV patients. This study was designed to assess the immunogenic properties of genetically conserved
peptides derived from the C-terminal region of HVR-1 and test their neutralizing activities in a step towards
developing therapeutic and/or prophylactic immunogens against HCV infection. Antibodies were generated by
vaccination of goats with synthetic peptides derived from HCV E2. Viral neutralizing capacity of the generated anti
E2 antibodies was tested using in vitro assays. Goats immunized with E2 synthetic peptides termed p412 [a.a 412-
419], p430 [a.a 430-447] and p517 [a.a 517-531] generated high titers of antibody responses 2 to 4.5 fold higher
than comparable titers of antibodies to the same epitopes in chronic HCV patients. In post infection experiments
of native HCV into cultured Huh7.5 cells anti p412 and anti p 517 were proven to be neutralizing to HCV genotype
4a from patients’ sera (87.5% and 75% respectively). On the contrary anti p430 exhibited weak viral neutralization
capacity on the same samples (31.25%). Furthermore Ab mixes containing anti p430 exhibited reduced viral
neutralization properties. From these experiments one could predict that neutralization by Abs towards different
E2-epitopes varies considerably and success in the enrichment of neutralization epitope-specific antibodies may be
accompanied by favorable results in combating HCV infection. Also, E2 conserved peptides p517 and p412
represent potential components of a candidate peptide vaccine against HCV infection.
Keywords: Hepatitis C virus (HCV), anti E2 antibodies, neutralizing antibodies, In vitro culture model for HCV, candi-
date peptide vaccine for HCV
Introduction
Hepatitis C Virus (HCV) is a global health problem that
affects almost 3% of the world’sp o p u l a t i o n[ 1 ]a n dn o t
less than 15% of the Egyptian population [2]. Individuals
with chronic HCV infection usually remain asympto-
matic and undiagnosed for decades before chronic hepa-
titis leads to severe fibrosis and cirrhosis, hepatic failure,
or hepatocellular carcinoma [3-7]. These long-term
complications made HCV one of the leading emerging
infectious diseases worldwide. The current antiviral regi-
men, a combination of pegylated interferon a and riba-
virin, is curative in about half of treated patients
depending on the viral and/or host factors. Additionally,
this regimen is expensive, requires prolonged therapy,
sometimes with serious side effects and only a fraction
of those with chronic HCV infections meet the criteria
for treatment [8].
Viral proteins are recognized as non-self by the host’s
immune system and induce the production of antibo-
dies. During the natural course of infection, a large
number of antibodies are produced. The vast majority
of antibodies induced have no antiviral activity, either
because they are elicited by degraded or incompletely
processed proteins released from dying cells or because
they are directed against epitopes that do not play any
role in the virus entry process “non-neutralizing antibo-
dies”. A small proportion of antibodies termed “neutra-
lizing antibodies” are able to target exposed epitopes of
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virus by preventing or controlling viral infection [9,10].
During the chronic phase of HCV infection, most HCV-
infected patients develop high-titer of antibodies. Para-
doxically, these antibodies were not able to control
HCV infection which may be attributed to the genera-
tion of non-neutralizing HCV-specific antibodies that
compete with neutralizing Abs and reduce their effec-
tiveness. Such antibodies have been reported in other
viral infections in which highly immunogenic non-neu-
tralizing epitopes mislead the humoral immune response
contributing to viral escape from neutralization [11].
Several observations support the hypothesis that neutra-
lizing antibodies may help control HCV replication
[12,13].
Synthetic peptide based vaccines were shown to gen-
erate specific Abs capable of neutralizing HCV infec-
tions [14,15]. In the present study, we utilized large
scale multiple sequence alignment of E2 to design
genetically conserved peptides from viral envelop pro-
teins (particularly among type 4 isolates predominant in
Egypt). The aim of this work is to develop monospecific
polyclonal Abs in caprines against the 3 chosen con-
served peptides derived from E2 glycoprotein and to test
the immunogenic and viral neutralizing properties of
each Ab using assays depending on blocking of viral
infectivity to hepatoma cell line. Based on the obtained
results, p412 and p517 represent candidate peptides for
further assessment as potential therapeutic/prophylactic
immunogens.
Materials and methods
Approval ethics
This research was approved by the Review Board of
National Research Center, Egypt
Design and synthesis of HCV E2 conserved peptides
Three peptides were designed and synthesized as pre-
viously described [16]. Peptides were all derived from
the C-terminal region of HVR-1 and designated p412 [a.
a 412-419], p430 [a.a 430-547] and p517 [a.a 517-531].
Immunization of caprines, production and purification
of polyclonal antibodies
Six goats were immunized with either of the synthetic
peptides p412, p 430 or p517 (2 animals for each pep-
tide). Two goats were injected with 2 ml saline solution
at the same time intervals of immunization protocol to
serve as controls. The immunizing doses/goat were 1.5
mg of the peptide. Each linear peptide was emulsified
with equal volume of Freund’s complete adjuvant and
was injected subcutaneously in three different sites
within the same animal. On days 15 and 28, blood sam-
ples were collected and then each goat was reimmu-
nized with a second booster dose of the same peptide
emulsified with equal volume of Freund’s incomplete
adjuvant. The goats were sacrificed after 96 days from
the last injection and the blood was collected to quantify
the titer of relevant immunoglobulins. Caprine IgG was
purified out following a procedure described by Mckin-
ney and Parkinson, [17]. Briefly, IgG purification was
carried out in two steps, step 1 involves elimination of
albumin and other non IgG proteins via precipitation
with Caprilyic acid (Octanoic acid; Riedel-DE HAEN
AG, Seelze-Hannover, Germany). While step 2 includes
further purification of IgG fractions using ammonium
sulphate cut as reported by Mohanty and Elazhary [18].
Efficacy and specificity of purified caprine IgGs towards
the relevant E2 antigens in HCV infected human sera
Western blot analysis was used to detect circulating E2
proteins and/or relevant epitopes on HCV virions using
the purified caprine antibodies as previously described
[16,19,20]. In brief, strips with HCV serum proteins
were washed 3 times and incubated with diluted first
anti p412 Ab (1:100 in PBS-0.3% T20) at room tempera-
ture for 2 h. After 3 washes, strips were incubated with
anti-caprine IgG peroxidase labeled second Ab (KPL,
Gaithersburg, USA) diluted in 1: 5000 PBS-0.3% T for 2
h at room temperature. Visualization of bands on the
nitrocellulose membrane was done by incubating the
strips with 0.01 M PBS, pH 7.4 containing 50 mg, per-
o x i d a s es p e c i f i cs u b s t r a t e ,d i a m i n o b e n z e d i n eD A B
(Sigma; Deisenhofen, Germany) and 100 μl of 3% hydro-
gen peroxide.
Establishment of cell culture system infected with HCV
Cell line
Human well differentiated hepatocellular carcinoma cell
line Huh7 was modified to produce a more efficient cell
line Huh7.5 a generous gift from Charles Rice (The
Rockefeller University, USA). The cells were obtained
under Material Transfer Agreement (MTA# 642 to Dr.
Mostafa K. El Awady 2007). Huh7.5 cells were used for
HCV infection experiments and assessment of viral
replication. Huh7.50 cells were cultured and infected
with HCV particles according to protocols described by
Seipp et al., [21] and Song et al.,[22]. Assessment of the
successful viral infection in Huh7.5 cells throughout the
culture duration was confirmed at the transcriptional
level by Reverse Transcription Polymerase Chain Reac-
tion (RT-PCR) amplification of HCV RNA and at the
translational level by SDS-PAGE of cell lysates followed
by Western blotting to determine the de novo synthesis
of non structural proteins e.g NS5A. Western blot was
done as described before except that the membrane was
incubated with diluted mouse monoclonal anti-NS5A
(Ab, Abcam; Cambridge, UK) (1: 200 in PBS-0.3% T) at
room temperature for 2 h and after the 3 washes, the
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with diluted peroxidase labeled anti-mouse IgG Ab (1:
1000 in PBS-0.3% T). For Reverse transcription -PCR
(RT-PCR), retrotranscription was performed in 25 μl
reaction mixture containing 20 units of AMV reverse
transcriptase (Clonetech, USA) with 400 ng of total cel-
lular RNA as template, 40 units of RNAsin Clontech,
USA), a final concentration of 0.2 mmol/l from each
dNTP (Promega, Madison, WI, USA) and 50 pmol of
the reverse primer P1. The reaction was incubated at
42°C for 60 min. and denatured at 98°C for 10 min.
Amplification of the highly conserved 5’-UTR sequences
was done using two rounds of PCR with 2 pairs of
nested primers. The first round amplification was done
in 50 μl reaction containing 50 pmol from each of P2
forward primers and P3 reverse primers, 0.2 mmol/l
from each dNTP, 10 μl from RT reaction mixture as
template and 2 units of Taq DNA polymerase (Promega,
USA) in 1 × buffer supplied with the enzyme. The ther-
mal cycling protocol was as follows: 1 min at 94°C, 1
min at 55°C and 1 min at 72°C for 30 cycles. The sec-
ond round amplification was done as the first round,
except for use of the nested reverse primer P4 and for-
ward primer P5 at 50 pmol each. A fragment of 172 bp
was identified in positive samples. Primer sequences are
as follows: P1: 5’ggtgcacggtctacgagacctc 3’;P 2 :5 ’ aac-
tactgtcttcacgcagaa 3’;P 3 :5 ’ tgctcatggtgcacggtcta 3’;P 4 :
5’ actcggctagcagtctcgcg 3’; P5: 5’ gtgcagcctccaggaccc 3’
Testing the immunoreactivity of caprine anti p412
antibody with intracellular E2 protein
Intracellular expression of E2 antigen in infected Huh7.5
cells was confirmed via 3 independent immuno assays;
namely western blotting, intracellular immunosaining
and FACS analysis. Western blotting was performed as
previously mentioned. Intracellular HCV immunostain-
ing assay was achieved as follows: Cells (either infected
or non infected) were grown in 6 well cell culture plates
(Greiner Bio-one, Germany) for 48 h to semi-con-
fluency. Prior to staining, cells were washed with PBS
and immunostained according to a procedure described
by Harlow and Lane [23]. Briefly, cells were fixed with
4% paraformaldehyde solution in PBS for 10 min at
room temperature and then washed twice with PBS.
Fixed cells were permeabilized by incubation in 0.2%
TritonX-100 in PBS for 15 min, followed by washing 3
times with PBS. Blocking the non-specific antibody
binding sites was done by incubating cells for 10 min in
blocking buffer (PBS-1% BSA). Cells were incubated
with anti p412 Ab at dilution 1/200 in PBS -1% BSA for
1 h at room temperature. Cells were then washed 3 X
with PBS, 10 min each wash. Horseradish peroxidase
conjugated anti-caprine IgG (KPL, Gaithersburg, USA)
at dilution 1/2000 in PBS-1% BSA was added to the
monolayer cells and incubated for 1 h at room tempera-
ture. Colored foci were revealed by incubating the cells
with 0.01 M PBS, pH 7.4 containing 50 mg, peroxidase
specific substrate, diaminobenzedine (Sigma; Deisenho-
fen, Germany) and 100 μlo f3 %h y d r o g e np e r o x i d ea n d
stopped after 10 min of incubation with distilled water.
The distinct colored foci were examined and some posi-
tive and negative fields were photographed on phase
contrast microscope (Olympus IX70, USA). To further
analyze the immunoreactive properties of caprine anti
p412 Ab antibody with the E2 antigen localized on the
surface of Huh7.5 cells, FACS analysis of HCV E2 anti-
gen was performed on surface of infected Huh7.5 cells
as follows: cells were infected with a pool of high HCV
viral loads. The plates were incubated at 37°C with
media change every two days. After one week incuba-
tion, media were aspirated and cells were washed three
times with PBS, collected then centrifuged and superna-
tants were removed. Cell pellets were washed 4 times
with PBS. Surface labeling was performed by indirect
immuno-fluorescence, where cells were incubated with
anti p412 Ab (at dilution 1/200 in PBS) for 1 h at 4°C,
and washed 4 times with PBS. Fluorescein isothiocya-
nate (FITC) labeled anti Caprine IgG (KPL, Gaithers-
burg, USA) at dilution 1: 2000 in PBS was added to the
cells for 30 min at 4°C. Cells were washed 3 times with
PBS containing 1% normal caprine serum to decrease
nonspecific fluorescence, then cells were suspended in
500 μl PBS and analyzed with BD FACS Calibur™ Flow
Cytometer (Becton Dickinson, USA). Mean fluorescence
intensities were determined using cell Quest software
(Becton Dickinson, USA).
Testing the viral neutralizing capacity of caprine anti E2
antibodies
Viral neutralizing activity of caprine anti E2 antibodies
was studied using HCV infected Huh7.5 and pursuing
the viral replication via RT-PCR amplification. In order
to study the antibody mediated neutralization, different
concentrations of the generated E2 antibodies were pre-
incubated with a pool of 10 HCV genotype 4a infected
sera with viral loads ranging from 9 × 10
5-1.5 × 10
6
copies/ml prior to incubation with Huh7.5 cells. Viral
binding/entry to cells was detected by nested RT-PCR.
In a 1.5 ml tube, HCV positive sera that were pre-
diluted with FCS free media (1: 50) was incubated with
serial dilutions of caprine anti E2 antibodies from 150
μg/ml to 2.5 μg/ml in a final volume of 1 ml FCS-free
DMEM. Pooled HCV positive sera as well as HCV nega-
tive (negative HCV RNA and IgG Abs) were diluted
1:50 in 1 ml FCS-free DMEM and used for infection
assays as positive and negative controls respectively. All
tubes were then incubated overnight at 4°C before sup-
plementation to cells. Huh7.5 cells (200,000 cells/well)
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10% FCS, 1% Penicillin-Streptomycin and 0.1% fungi-
zone in 6 well plates for 48 h. The media were aspirated,
then cells were washed twice with FCS-free medium and
inoculated with 1 ml of the previously incubated sera-
antibody mix. For each assay, two wells were left with-
out serum inoculation (supplied only with DMEM) to
serve as reagent negative controls. After 90 minutes at
37°C in 5% CO2, 1 ml DMEM containing 10% FCS was
added to each well. On the next day media were aspi-
rated and cells were washed three times with PBS to get
rid of the remaining sera-antibody mix, replaced with
fresh medium (DMEM-10% FCS) and cells were further
incubated for 24 h at 37°C. On the third day, media
were aspirated and 500 μl of (4 M guanidinium thiocya-
nate/0.5% sarcosyl) was added to each well. Extraction
of total cellular RNA was done as described by El
Awady et al [19]. Amplification of of HCV RNA was
performed using 5’UTR specific nested primers as stated
above.
Effect of HCV viral load on infectivity of Huh7.5 cultured
cells and on the blocking activity of the generated
caprine antibodies
To test whether the viral load in HCV positive samples
affects viral entry into Huh7.5 cells or the blocking
activity of the generated caprine antibodies, viral loads
were quantified in 20 samples prior to application in the
infection experiments. A statistical correlation was made
between viral loads in each sample and the blocking
activity of the generated caprine antibodies. T- Test was
conducted to correlate both parameters. Testing the
blocking of viral entry into hepatoma cells by different
combinations of caprine anti E2 antibodies
To test the possible molecular and/or steric interfer-
ence of a combination of two caprine anti E2 antibodies
on blocking of viral entry into cultured Huh7.5 cells, a
p o o lo f1 0H C V4 ap o s i t i v es e r aw e r ep r e - i n c u b a t e d
with the following 3 Ab combinations (anti p412 + anti
p430), (anti p412 + anti p517) and (anti p430+ anti
p517) prior to infection of cells. Viral RNA was
extracted and subjected to intracellular viral evaluation
using both nested RT-PCR as previously described and
quantitatively by Real Time PCR (Qiagen, CA USA),
w h e r eas i n g l e - t u b er e a lt i m eR T - P C Ra s s a yw a sp e r -
formed for the quantification of the 5’ NCR of HCV by
using Taqman technology [Roche Molecular Diagnostics
Systems].
Statistical analyses
All statistical analyses were performed using the SPSS
9.0 statistical software program. The difference is con-
sidered statistically significant when p ≤ 0.05.
Results
Specificity of purified caprine IgG in detection of
circulating E2 antigen in HCV positive sera
Figure 1 shows the purified IgG that was subsequently
used in western blot analysis. The resolved HCV pro-
teins from infected patients were electrotransferred onto
nitrocellulose membrane and allowed to react with puri-
fied IgG from p412 immunized goats. A discrete band
at ~ 58 kDa appeared only in HCV positive sera but
could not be detected in healthy sera (Figure 2) indicat-
ing the presence of a circulating HCV specific antigen
possibly E2 in infected serum samples. ELISA and Dot
EIA assays demonstrated a high binding affinity of the
generated IgG’s towards the corresponding synthetic
peptides in a peptide specific fashion as previously
s h o w ni nE lA w a d yet al., [16] indicating the absolute
specificity of IgG epitope interaction.
Evaluation of Huh7.5 hepatoma cells’ support of HCV
replication in vitro
Direct infection of Huh7.5 cells from positive HCV sera
resulted in a detectable intracellular levels of both geno-
mic (Figures 3 and 10b) and antigenomic (Figure 3)
strands thus suggesting intracellular genomic replication
of HCV. Western blot analysis to test the expression of
viral NS5A (non structural) protein in lysates of infected
Huh7.5 cells
To examine whether infection of Huh7.5 cells with
pooled HCV positive sera resulted in viral replication
and de novo synthesis of non structural proteins, a
mouse monoclonal antibody to NS5A protein was
employed as a primary antibody to detect intracellular
NS5A antigen within the resolved cell lysates. A distinct
recognizable band at ~ 56 kDa (Figure 4) corresponding
to newly synthesized NS5A protein was only detected in
infected cells, indicating that these cells do support
expression of viral non structural proteins.
Testing the immuno-reactivity of caprine anti E2 Abs with
Huh7.5 expression of E2 antigen
Three approaches were followed to test this immunor-
eactivity, namely western blot, immunocytochemistry
and FACS analysis.
a) Western blot analysis of infected Huh7.5 cells using
caprine anti p412 Ab to detect intracellular viral E2
antigens.
To determine whether the generated caprine antibo-
dies were able to react with intracellular E2 antigen as a
structural protein, western blot hybridizations of HCV
infected cell lysates were compared with lysates from
uninfected cells. Caprine anti p412 Ab could detect the
expression of two immunogenic proteins of molecular
weights ~115 and 75 kDa that were not detectable in
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obtained when using anti p430 and anti p517 Abs.
b) Intracellular HCV immunostaining assay
To confirm the observed immunoreactivity of caprine
Abs in detecting the intracellular viral E2 proteins,
either in a form of free antigen or on surface of viral
particles, HCV infected or uninfected Huh7.5 cells were
immunostained as described in Materials and Methods
using anti p412 as a primary Ab. The results shown in
Figure 6 indicate great specificity of caprine Abs where
only infected cells contained distinct colored foci that
were not detected in uninfected cells.
c) Flow Cytometric analysis of HCV E2 expression on
surface of Huh7.5 cells using caprine anti p412 Ab.
To test whether expressed E2 antigen in infected
Huh7.5 cells was detectable by caprine Abs generated
against E2 derived epitopes, surface staining of HCV E2
antigen in infected Huh7.5 cells was performed by indir-
ect immuno-fluorescence. Cells were incubated with
anti p412Ab, stained with FITC labeled antigoat Ab and
analyzed with flow cytometer. Results in Figure 7
Figure 1 Two step partial purification of caprine IgG’s from E2 synthetic peptide immunized caprines. Caprine sera before (lane 1) and
after purification of p412, p430 and p517 (lanes 1, 2 and 3 respectively) immunized caprine sera were resolved on SDS PAGE followed by
Coomassie blue staining. The caprine albumin appears as a dense band at ~ 64 kDa in unpurified serum and much less dense in purified sera.
Lanes 1, 2 and 3 show distinct bands of heavy and light chain IgG at 53 and 26 kDa after purification. Lane M represents the Broad Range
Protein Molecular Weight Marker (Promega; Madison, USA).
Figure 2 Western blott analysis showing the ability of the
generated caprine antibodies to recognize the E2 protein in
HCV infected sera. After SDS-PAGE on 12% gels under non
reducing conditions, resolved proteins were electrically transferred
into nitrocellulose membranes and enzyme immune reaction was
developed. Lanes 1 and 2 represent sera of healthy individuals as
negative controls. Lanes3, 4 and 5 represent sera from three HCV
infected patients. A band of ~ 58 kDa was detected only in HCV
positive but not in healthy sera. M lane represents the molecular
weight protein marker.
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infected Huh7.5 cells was significantly higher than the
uninfected Huh7.5 cells thus demonstrating the marked
sensitivity and specificity of anti p412 Ab immunoreac-
tivity towards E2 protein. Similar results were also
obtained when either caprine anti p430 or p517 Abs
were used indicating similar immunoreactive properties
of all E2 derived Abs used in this study.
Effect of caprine anti E2 Abs on HCV 4a RNA replication
in Huh7.5 cells
a) Titration of Ab concentration achieving viral
neutralization
Figure 3 Agarose gel electrophoresis of nested RT-PCR products to evaluate HCV infection into Huh7.5 cells from HCV positive sera.
The HCV nested RT-PCR products at 174 bp band were visualized on 2% agarose gels stained with ethidium bromide. Lane 1: viral positive
strand in the HCV genotype 4 patients’ sera. Lane 2: viral positive strand in the patients’ PBMCS. Lane 3: negative strand in the patients’ PBMCS.
Lane 4: nested RT-PCR product of the last wash of Huh7.5 cells to make sure there isn’t ny residual virus from the infectious serum. Lane 5: viral
positive strand in the cells 3 days post infection. Lane 6: viral negative strand in the cells 3 days post infection. Lane 7: viral positive strand in the
supernatant 3 days post infection. Lane 8: viral negative strand in the cells’ supernatant. M: molecular weight standard DNA marker (100 base
pair; Jena Bioscience, Germany).
Figure 4 Western blott analysis to test de novo synthesis of
non structural protien (NS5A) of HCV in lysates of infected
Huh7.5 cells. Huh7.5 cells were infected a pool of 20 HCV positive
samples. Cells were lysed as described in Materials and Methods
and the lysates were resolved on 12% SDS-PAGE, blotted onto
nitrocellulose membranes and hybridized to anti-NS5A monoclonal
antibody as primary antibody and the color was developed
enzymatically with anti mouse IgG as secondary antibody. A distinct
specific band of ~ 56 kDa corresponding to the NS5A protein
appeared only in infected (lane 2) but not in the uninfected (lane 1)
cells indicating de novo synthesis of viral non structural proteins
following infection with the virus. Lane M represents the Protein
marker (Blue Ranger Pre-stained Marker Mix; Pierce, U.S.A).
Figure 5 Western blott analysis to test the efficacy of anti
p412 caprine antibody to recognize the corresponding
intracellular viral antigens. Huh7.5 cells were infected with pooled
HCV positive sera. Cell lysates were subjected to western blotting
analysis using caprine anti p412 antibody. Two proteins of
molecular weights 115kDa and 70kDa appeared only in HCV
infected cells (lane 1) but not in uninfected cells (lane 2). M
represents the Protein marker (Blue Ranger Prestained Marker Mix;
Pierce, U.S.A).
El Abd et al. Virology Journal 2011, 8:391
http://www.virologyj.com/content/8/1/391
Page 6 of 12Testing the neutralizing activity of serial Ab concen-
trations (Figure 8) demonstrated that 10 μg/ml from
anti p412 Ab had the highest neutralizing activity on
HCV entry and replication.
b) To test whether caprine Abs towards different E2
epitopes elicit the same blocking activity on HCV repli-
cation in Huh7.5 cells, the latter were infected separately
with 20 HCV 4a positive sera, with varying values of
Figure 6 Immunostaining of infected Huh7.5 cells with anti p412 caprine antibody. Huh7.5 cell lines were infected with positive HCV sera
as described in Materials and Methods. Immunostaining was carried out after 5 days from infection. Anti p412 was used as a primary antibody
and anti-caprine peroxidase as a secondary antibody. DAB was used as substrate. Brown foci were visualized in infected cells (B) but not in non
infected cells (A).
Figure 7 A single parameter histogram for Flow Cytometric analysis of HCV E2 expression on surface of Huh7.5 cells using caprine
anti p412 Ab. Huh7.5 cells were infected with pooled HCV positive sera. After one week cells were harvested and incubated with caprine anti
p412 Ab, washed and stained with FITC labeled anti goat Ab. Labeled cells were analyzed with flow cytometry (FACS Calibure, Becton
Dickinson). Results showed that the mean fluorescence intensity of the infected Huh7.5 cells (B &D) was markedly higher (30%) than the
uninfected Huh7.5 cells (A & C) demonstrating the specificity of anti p412 Ab to recognize the E2 protein on surface of HCV infected cells.
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either caprine anti p430, anti p517 or anti p412 purified
Abs in the culture medium. Intracellular HCV RNA was
extracted, nested RT-PCR amplified and resolved on 2%
agarose gel. The results show that this method exhibited
80% efficiency of viral infection into Huh7.5 cells.
Furthermore, anti p517 and anti p412 Abs exhibited the
highest potency in blocking of viral replication in cells
( 7 5 %a n d8 7 . 5 %r e s p e c t i v e l y )a sc o m p a r e dw i t ha n t i
p430 Ab (31.5%). These results were confirmed by find-
ings displayed in Figure 9 produced after infecting
Huh7.5 cells with a pool of HCV 4a positive sera and
incubation with the 3 tested caprine Abs at decreasing
concentrations of purified Abs (10 - 2.5 μg/ml). Figure 9
showed that the tested range of anti p517 and anti p412
Ab concentrations did induce total inhibition of intra-
cellular viral replication, whereas anti p430 Ab failed to
induce inhibition of HCV replication at concentrations
below 10 μg/ml.
c) Interference exerted by non neutralizing Abs on
viral neutralization
The possible steric hindrance of anti p430 Ab on the
couple of neutralizing E2 Abs; namely anti p412 and
anti p517 Abs were demonstrated in Figure 10(a) and
10(b) where anti p430 Ab induced significant interfer-
ence with the viral neutralization capacities of both anti
p412 and anti p517 Abs.
Discussion
Three synthetic peptides were mapped to conserved epi-
topes within the carboxy terminal region of the HVR-1 of
E2 protein. These immunogenic peptides were selected to
be genetically conserved at least among viral subtypes
infecting the local population, predominantly 4a. The pep-
tide p430 showed 88% homology with HCV genotype 4a
while p517 and p412 showed 93% and 100% homology
respectively [16]. The present data demonstrate that
immunization of caprines with these peptides can elicit
significant humoral responses and the generated Abs were
able to recognize relevant epitopes, either as the free solu-
ble antigen or on surface of HCV particles in sera of
chronically infected patients, thus suggesting its usefulness
as specific diagnostic reagents. The expression of E2
related peptide in western blots at 58 kDa upon treatment
with caprine IgG only in HCV positive sera confirms ear-
lier data [24] that it represents a deglcosylated E2 protein
and suggests the presence of immunodominant conserved
epitopes within the E2 gp which encompass motifs of sev-
eral linear epitopes. We have recently shown that these
linear epitopes stimulated humoral and cellular responses
in caprines [16] and in mice [25]. The observed immunor-
eactivity of these peptides with human IgG in HCV posi-
tive patients suggest that those E2 epitopes are
immunogenic in humans, a hypothesis awaiting confirma-
tion in future testing of healthy volunteers.
Figure 8 Agarose gel electrophoresis of nested RT-PCR products to determine the neutralizing doses of the generated goat E2
antibodies. The neutralizing dose of anti p517 and anti p412 started at 10 μgm/ml and continued to, as low as, 2.5 μgm/ml while the least
and only neutralizing dose of anti p430 was 10 μgm/ml.
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strong candidate receptor that enables HCV particles to
bind to cells [26,27]. We have clearly demonstrated that
direct infection of Huh7.5 cells from HCV positive sera
resulted in viral entry into the cells as indicated by con-
siderable quantities of intracellular viral RNA genomic
and antigenomic strands throughout the duration of cell
culture. The viral entry was followed by de novo
Figure 9 Agarose gel electrophoresis of nested RT-PCR amplification of intracellular HCV RNA following incubation with decreasing
concentrations of anti E2-epitopes caprine antibodies. Huh7.5 cells were infected Invitro using a pool of 10 HCV genotype 4 positive sera
with viral loads ranges (9 × 10
5-1.5 × 10
6 copies/ml) in absence (lane 1) and presence (lanes 2-10) of serial dilutions (10 - 2.5 ug/ml) of caprine
Abs. Cellular RNA was amplified using HCV 5’UTR specific nested primers as described in Materials and Methods. Agarose gel shows the status of
Ab inhibition; anti p430 (A, lanes 2, 3, 4), anti p517 (B, lanes 5, 6, 7) and anti p412 (C, lanes 8, 9, 10). M is a molecular weight standard DNA
marker (100 basepair; Jena Bioscience, Germany). Lane 11 shows the results of normal non infected Huh7.5 cells (negative control).
Figure 10 Neutralizing activities of combinations caprine E2 antibodies as measured by RT-PCR and real time PCR. Figure 10a Agarose
gel electrophoresis of nested RT-PCR products of HCV 4a infected Huh7.5 cells to assess the optimum combinations of caprine E2 antibodies
that block the viral infection into cells. Huh7.5 cells were infected Invitro using (virus + Ab) mixes each was made up of a pool of 10 HCV 4a
positive sera (1.5 × 10
6-3 × 10
6 copies/ml) mixed with different combinations of caprine anti p430, anti p517 and anti p412Abs. Cells were
preincubated with virus/Ab mixes overnight at 4°C. Cells incubated with HCV pool serve as positive control; lane 1. Mixes containing anti p430
showed partial inhibition of intracellular viral replication (lanes 2 and 3). Total blockage of HCV RNA replication inside Huh7.5 cells was achieved
by a combination of caprine anti p517 and anti 412 Abs (lane 4). Products of non-infected Huh7.5 cells as negative control were presented in
lane 5). M is a molecular weight standard DNA marker (100 basepair; JenaBioscience, Germany). Figure 10b Qualitative evaluation of combined
effect of goat E2 antibodies that block HCV infection invitro. The results obtained revealed that although the mix of goat anti peptides 430 &
517 and the mix of anti p430 & anti p412 didn’t block the viral replication but yet it was delayed such that the amplification started at cycle 32
and cycle 33, respectively, instead of cycle 16 as it was shown for the infected Huh7.5 cells (positive control). On the other hand the mix of the
goat anti p412 & anti p517 showed, similar results as in negative control uninfected Huh7.5 cells, without any significant amplification (below
the cutoff line), indicating complete viral inhibition.
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E2 and NS5A suggesting that these cells support the de
novo expression of viral proteins. The appearance of
two immunogenic peptides 70 and 115 kDa in infected
Huh7.5 cells represent E2 protein and E1/E2 dimer
respectively, thus supporting previous reports [28-30].
Since NS5A is not detectable in HCV positive sera its
detection in cell lysates represents a marker for efficient
infection and intracellular HCV replication [31]. Infected
Huh7.5 cells were able to shed virus into culture med-
ium, where the later could efficiently infect naïve
H u h 7 . 5c e l l s( r e s u l t sn o ts h o w n ) .I n f e c t i o no fc e l l sin
vitro with HCV from a variety of sources can at least
demonstrate the infectivity of the virus making these
systems useful in evaluating drugs for antiviral activity
or inhibition of HCV replication [19,22,32]. Transfection
with synthetic full-length or near-full-length HCV RNA
has the drawback that the RNA used for transfection is
homogenously synthesized containing well defined
sequence whereas in cases of natural infection with the
whole viral particles several quasispecies of different
magnitudes of infectivity could be coexisting, thus
mimicking the in vivo infections of HCV. Other disad-
vantage of synthetic subgenomic virus transfection could
be the absence of one or more non structural genes,
which does not allow assembly of infectious viral parti-
cles as demonstrated by failure to infect chimpanzees
[33]. When the full viral genome was put in frame
downstream a strong promoter, it is obviously expected
that the replication and the regulation of expression of
viral proteins will not take place under viral regulatory
elements. Besides, the system has the limitation of being
restricted to single quasispecies and the chances of var-
iant production, mimicking the natural infection, are
poor.
In the present study we thought that not all antibodies
raised against conserved peptides are neutralizing.
Although caprine anti p430 Ab did not interfere with
HCV entry at concentrations below 10 μg/ml, caprine
anti p412 and p517 Abs, on the other hand, were able
to block HCV entry into cells at concentration as low as
2.5 μg/ml, suggesting that the later two Abs are poten-
tially neutralizing. The reason why high Ab concentra-
tions did not neutralize the virus could attributed to
aggregation and inability to bind to their corresponding
epitopes, [34] a phenomenon previously referred to as
zone tolerance between the amounts of Ab relative to
its Ag. In general, the current data confirm our earlier
results that caprine anti p412 and anti p517 Abs could
bind HCV in immuncapture experiments while anti
p430 Ab could not [16]. This agrees to earlier findings
of Zhang et al., [11] who mapped two epitopes within a
short segment of E2: epitope I, at amino acids 412-419
and epitope II, at amino acids 434-446 and
demonstrated that epitope I, but not epitope II, was
involved in virus neutralization under their experimental
conditions, using HCV genotype 2a. The region encom-
passing amino acids 432-447 can be recognized by at
least three monoclonal antibodies. Hsu et al., [35] using
HCV pseudoparticle assay de m o n s t r a t e dt h a tt h e s e
MAbs were involved in viral neutralization. Knowing
that genotypes 1, 4, 5, and 6 are serologically more clo-
sely related to each other than to genotypes 2 and 3
[36], the possibility that epitope II in various genotypes
is associated with neutralization could not be excluded.
Needless to say, assay systems and virus genotypes used
in different studies may explain different outcomes of
neutralization studies. To examine the possibility that
anti p430 Ab displays a steric/or masking effect on the
viral neutralization properties exerted by either anti
p412 or anti p517 Abs, we performed viral neutraliza-
tion assays in presence of a variety of Ab mixes. The
current results clearly demonstrate that anti p430 Ab
displayed a negative effect on the other two Abs so that
it demolished their neutralizing activities, while a mix-
ture of anti p412 and anti p517 exhibited potent viral
neutralization properties either as singles or in combina-
tions. These in vitro experiments perhaps explain the
observed failure of viral neutralization and/or clearance
in chronic HCV patients despite the presence of a pool
of E2 Abs in their sera. These findings suggest that
caprine anti p517 and anti p412 Abs may have been
interfered by anti p430 Ab either at the level of viral
adsorption and/or entry into cells thus leading to failure
of inhibition of HCV replication inside the cells. This
conclusion confirms the hypothesis made by von Hahn
et al., [37], Stamataki et al., [38] and Zhang et al., [11]
that co-existence of non neutralizing and neutralizing
Abs may lead to hindrance of neutralizing activity in
chronic HCV patients.
The reason for the failure of Huh7.5 infection by 4 out
of 20 HCV positive sera is not clear; it is possible that
free b-lipoproteins in human serum compete with the
virus towards LDL receptors on surface of Huh7.5 cells
[39]. We cannot neglect other reports claiming that the
current in vitro system is not 100% permissible [40],
and that the efficiency of viral infection could not be
predictable for a given sample. Besides, the present data
showed that no obvious correlation could be drawn
between infectivity and viral RNA titer thus confirming
early results of Rumin et al.,[41]. Although the two can-
didate neutralizing Abs i.e. anti p412 and anti p517 Abs
displayed 87.5% and 75% viral neutralization efficiency
(table 1), at least two possible explanations do exist for
failure to inhibit viral infection in 12.5% and 25% of
cases respectively; 1) the presence of escape mutants of
viral isolates leading to failure to block mutants by capr-
ine Abs thus allowing viral entry and replication and/or
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protein released to serum from ruptured infected liver
cells and varies in quantities from patient to patient
[42].
Liver transplant recipients mostly suffer re-infection of
grafts shortly after transplantation. One approach to
control re-infection is the combined use of specific anti-
viral together with HCV-specific antibodies [43]. So we
anticipate that the long term benefit of this study will
be to generate fully human monoclonal antibodies
against HCV E2 synthetic peptides derived from geneti-
cally conserved regions and use as supplement to IFN
based therapy in post transplants of HCV positive
patients. One could also predict that exclusive adminis-
tration of neutralizing epitopes would be rather ade-
quate to confer prophylaxis against early exposure to
HCV infection. In conclusion, taking together the results
of humoral immunity and cellular responses suggest that
p412 and p517 peptides described herein are potential
candidates for designing a prophylactic and/or therapeu-
tic vaccine against HCV for further clinical studies.
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